529 episodes
Jefferies London 2026: IDEAYA Biosciences Founder & CEO Yujiro Hata shares an update on darovasertib, which is in front of FDA for Uveal Melanoma, and talks DLL3 and PRMT5
11/18/2026 | 11 mins.He describes the darovasertib filing, which IDEAYA hopes will be for all metastatic uveal melanoma patients. Plus, what makes DLL3 a compelling target, and how interest in PRMT5 has especially taken off given how prevalent MTAP deletions are in pancreatic cancer.Jefferies London 2026: Forbion, the most active lead investor in private biotech financing rounds globally last year, raised €2.3 billion across two new funds last month
11/18/2026 | 12 mins.Co-Owner and Managing Partner Sander Slootweg discusses the new funds and what kind of companies the funds might be deployed towards. He also shares his ideas and recommendations on how to make Europe more competitive in life sciences and keep companies in the region, and gives his take on the sector's outlook in 2027.Jefferies London 2026: APOL1-mediated kidney disease affects over 1 million people in the United States - Maze Therapeutics hopes to deliver a solution
11/18/2026 | 13 mins.CEO Jason Coloma describes the unmet need in this area - which affects younger people compared to most other chronic kidney conditions. He walks us through MZE829, which just completed enrollment the phase 2 HORIZON trial and will have data in early 2027.Jefferies London: When Celgene's powerhouse myeloma treatments emerged, it wasn't known that they were protein degraders. With today's advances in science, C4 aims to have a best in class degrader
11/18/2026 | 12 mins.President and CEO Andrew Hirsch describes the concept of protein degraders in general, and the paper that sparked the creation of C4 as a company. He discusses the company's registration intended trial, and another one in combination with a T-cell engager from Pfizer.Jefferies London 2026: Zealand Pharma CEO Adam Steensberg gives an update on the company's amylin program and comments on recent data from its Boehringer partnered glucagon/GLP-1
11/18/2026 | 14 mins.He shares his strong belief that for most people taking obesity medicines going forward, tolerability could be the most important factor of choice, which is amylin's strong suit.
Listen to BiotechTV - News, Stuff To Blow Your Mind and many other podcasts from around the world with the radio.net app

Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features












